Related Experiment Video

Updated: May 11, 2026

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

A potent and selective small-molecule inhibitor for the lymphoid-specific tyrosine phosphatase (LYP), a target

Yantao He1, Sijiu Liu, Ambili Menon

  • 1Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, 635 Barnhill Drive, Indianapolis, Indiana 46202, USA.

Journal of Medicinal Chemistry
|May 30, 2013
PubMed

Insights

Researchers identified compound 8b, a potent inhibitor of lymphoid-specific tyrosine phosphatase (LYP), a key player in autoimmune diseases. This discovery offers a promising avenue for developing new treatments for autoimmune disorders.

Area of Science:

  • Biochemistry
  • Immunology
  • Medicinal Chemistry

Background:

  • Lymphoid-specific tyrosine phosphatase (LYP) is implicated in various autoimmune diseases.
  • Protein tyrosine phosphatases (PTPs) are critical signaling enzymes in cellular processes.

Purpose of the Study:

  • To optimize a series of 6-hydroxy-benzofuran-5-carboxylic acids as LYP inhibitors.
  • To identify a potent and selective LYP inhibitor for potential therapeutic use.

Main Methods:

  • Structure-based drug design and lead optimization.
  • X-ray crystallography to determine LYP-ligand complex structure.
  • In vitro biochemical and cellular assays to assess inhibitor potency and selectivity.

Main Results:

  • Identified compound 8b, a potent LYP inhibitor with a K(i) of 110 nM.
  • Compound 8b demonstrated >9-fold selectivity over other PTPs.
  • Compound 8b showed cellular activity in T- and mast cells and blocked anaphylaxis in mice.

Conclusions:

  • Compound 8b is a highly effective and selective LYP inhibitor.
  • The structure of LYP complexed with 8b provides insights into molecular recognition.
  • Compound 8b represents a valuable starting point for developing LYP inhibitors for autoimmune diseases.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: